J. Sachs

发表

Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

M. Sykes, H. Eom, R. Chakraverty, 2006, Blood.

Extracranial Metastases of Glioblastoma in a Child: Case Report and Review of the Literature

M. Proctor, H. Lidov, N. Ullrich, 2007, Journal of pediatric hematology/oncology.

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Stephen X. Zhang, K. Neville, T. Klingebiel, 2018, The Lancet. Haematology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. Connors, K. Savage, Y. Oki, 2017, The New England journal of medicine.

Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency.

J. Orange, R. Geha, S. Pai, 2008, The Journal of allergy and clinical immunology.

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.

M. Sykes, Y. Yang, D. Pearson, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Nonalloreactive T Cells Prevent Donor Lymphocyte Infusion–Induced Graft-versus-Host Disease by Controlling Microbial Stimuli

R. Bronson, M. Sykes, H. Li, 2012, The Journal of Immunology.

Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance

S. Winski, J. Sachs, K. Bouhana, 2021, Blood.

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

T. Tashi, C. Ustun, V. Pullarkat, 2022, Blood.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

Phase 1/2 Study of Brentuximab Vedotin in Pediatric Pts with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 HL Data

K. Neville, F. Locatelli, S. Daw, 2014 .

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

K. Neville, S. Daw, Angelo Rosolen, 2013 .

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Robin L. Jones, W. Tap, M. Heinrich, 2023, Journal of Clinical Oncology.